{
    "clinical_study": {
        "@rank": "48662", 
        "arm_group": {
            "arm_group_label": "VS-6063 (defactinib)", 
            "arm_group_type": "Experimental", 
            "description": "Administered orally (BID) for 12 days (+/- 2 days)"
        }, 
        "brief_summary": {
            "textblock": "This is an open label neoadjuvant (treatment with VS-6063 prior to mesothelioma surgery)\n      study in subjects with malignant pleural mesothelioma who are eligible for surgery.\n      Subjects will receive VS-6063 (defactinib) for 12 days.  Pre- and post-treatment biopsies\n      and blood samples will be collected.  The purpose of this study is  to assess biomarker\n      responses from tumor tissue. The safety, pharmacokinetics, and tumor response rate to\n      VS-6063 (defactinib) will be also be assessed."
        }, 
        "brief_title": "Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Pleural Mesothelioma", 
        "condition_browse": {
            "mesh_term": "Mesothelioma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed malignant pleural mesothelioma that is not metastatic or\n             unresectable\n\n          -  Eligible to undergo excisional surgery such as extrapleural pneumonectomy (EPP) or\n             pleurectomy/decortication (P/DC) or any other mesothelioma surgery.\n\n          -  Localized disease. The malignancy is confined to one affected hemithorax.\n             Mediastinal N2 lymph nodes via cervical mediastinoscopy or EBUS (endobronchial\n             ultrasound) must be negative in order to be eligible\n\n          -  Grossly normal pulmonary, cardiac function, renal, hepatic hematologic and\n             performance functions\n\n          -  Male or non-pregnant female\n\n          -  Age  \u2265 18 years of age\n\n          -  Tissue is required prior to enrollment. If patient was diagnosed outside and tumor\n             tissue is not available, a pleural biopsy for frozen tissue collection is required.\n\n        Exclusion Criteria:\n\n          -  Participants who have had chemotherapy or radiotherapy any time  prior to entering\n             the study or at any prior time for mesothelioma. Patients receiving chemotherapy type\n             drugs for benign conditions can participate in this trial\n\n          -  History of upper gastrointestinal bleeding, ulceration, or perforation within 12\n             months prior to the first dose of study drug\n\n          -  Known history of Gilbert's Syndrome or any current hyperbilirubinemia of any cause\n\n          -  Known history of stroke or cerebrovascular accident within 6 months prior to the\n             first dose of study drug\n\n          -  Subjects with known infection with human immunodeficiency virus (HIV) or Acquired\n             Immune Deficiency Syndrome (AIDS)\n\n          -  Subjects with confirmed Hepatitis A, B or C\n\n          -  Subjects being actively treated for a secondary malignancy or any malignancy within\n             the last 5 years, with the exception of non-melanomatous skin cancer or localized,\n             definitively treated cervical cancer\n\n          -  Uncontrolled or severe cardiovascular disease, including myocardial infarct or\n             unstable angina within 6 months prior to study treatment, New York Heart Association\n             (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring\n             medication for treatment, clinically significant pericardial disease, or cardiac\n             amyloidosis\n\n          -  Known history of malignant hypertension\n\n          -  Uncontrolled intercurrent illness including symptomatic congestive heart failure,\n             cardiac arrhythmia, or psychiatric illness/social situations which in the opinion of\n             the study investigators would be associated with undue risk of participation in the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02004028", 
            "org_study_id": "VS-6063-203"
        }, 
        "intervention": {
            "arm_group_label": "VS-6063 (defactinib)", 
            "intervention_name": "VS-6063", 
            "intervention_type": "Drug", 
            "other_name": "defactinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Mesothelioma", 
            "adenoma", 
            "Neoplasms, Mesothelial", 
            "Focal Adhesion Kinase Inhibitor"
        ], 
        "lastchanged_date": "December 2, 2013", 
        "location": {
            "contact": {
                "email": "jbarlow1@partners.org", 
                "last_name": "Julianne Barlow", 
                "phone": "617-525-8541"
            }, 
            "contact_backup": {
                "email": "rbueno@partners.org", 
                "last_name": "Raphael Bueno, M.D.", 
                "phone": "617-732-8148"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02115"
                }, 
                "name": "Brigham and Women's Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Raphael Bueno, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "David J Sugarbaker, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "David Jackman, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael A Archer, D.O.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Window of Opportunity Phase II Study of the FAK Inhibitor VS-6063 in Participants With Surgical Resectable Malignant Pleural Mesothelioma.", 
        "overall_contact": {
            "email": "mkeegan@verastem.com", 
            "last_name": "Mitchell Keegan, Ph.D.", 
            "phone": "617-252-9320"
        }, 
        "overall_contact_backup": {
            "email": "rsorensen@verastem.com", 
            "last_name": "Rachel G Sorensen", 
            "phone": "617-252-9339"
        }, 
        "overall_official": {
            "affiliation": "Brigham and Women's Hospital", 
            "last_name": "Raphael Bueno, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine biomarker responses to the Focal Adhesion Kinase (FAK) inhibitor, VS-6063 (defactinib),  in Malignant Pleural Mesothelioma (MPM).", 
            "measure": "Assess biomarker responses to VS-6063 in tumor tissue", 
            "safety_issue": "No", 
            "time_frame": "From Baseline to 12 days (+/- 2 days) post-treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02004028"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse events will be graded by the CTCAE (Common Terminology Criteria for Adverse Events) 4.0 and summarized according to the worst grade observed since the first treatment dose.", 
                "measure": "Evaluate the safety of VS-6063 (defactinib)", 
                "safety_issue": "Yes", 
                "time_frame": "Start of treatment through 30 days after the end of treatment, expected average of 6 weeks"
            }, 
            {
                "description": "PK (pharmacokinetic) parameters will include but not limited to peak and trough concentrations and AUC (area under curve), clearance, and elimination half-life will be characterized by average and variation summaries in the population.", 
                "measure": "Evaluate the pharmacokinetics of VS-6063 (defactinib)", 
                "safety_issue": "No", 
                "time_frame": "Day 11 and Day 12 (+/-2) days post-treatment"
            }, 
            {
                "description": "Tumor response will be assessed by Recist 1.1 modified for mesothelioma. The response rate will be reported with 95% exact confidence intervals based on the exact binomial distribution.", 
                "measure": "To evaluate the tumor response to VS-6063 (defactinib)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 12 (+/-2) days post-treatment"
            }
        ], 
        "source": "Verastem, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Verastem, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}